Search

Your search keyword '"Gandolfi, Letizia"' showing total 170 results
Start Over Author "Gandolfi, Letizia"
170 results on '"Gandolfi, Letizia"'

9. Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis

Author

STEFONI, VITTORIO, BROCCOLI, ALESSANDRO, ARGNANI, LISA, PELLEGRINI, CINZIA, ZINZANI, PIER LUIGI, Maglie, Roberto, Gandolfi, Letizia, Stefoni, Vittorio, Broccoli, Alessandro, Argnani, Lisa, Maglie, Roberto, Pellegrini, Cinzia, Gandolfi, Letizia, and Zinzani, Pier Luigi

Subjects
Registrie, Adult, Male, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Middle Aged, Lymphoma, T-Cell, Transplantation, Autologous, Antineoplastic Agent, Young Adult, Retrospective Studie, Humans, Female, Registries, Human, Retrospective Studies
Abstract

no abstract available

Published
2014

11. The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients

Author

ZINZANI, PIER LUIGI, BROCCOLI, ALESSANDRO, CASADEI, BEATRICE, STEFONI, VITTORIO, PELLEGRINI, CINZIA, GANDOLFI, LETIZIA, ARGNANI, LISA, PILERI, STEFANO, FANTI, STEFANO, R. Maglie, P. L. Zinzani, A. Broccoli, B. Casadei, V. Stefoni, C. Pellegrini, L. Gandolfi, R. Maglie, L. Argnani, S. Pileri, and S. Fanti

Subjects
RITUXIMAB, PMLBCL, MACOP-B
Abstract

Regarding primary mediastinal large B-cell lymphoma (PMLBCL), there are several controversial topics that warrant further investigation: the superiority of third-generation regimens, the impact of rituximab, the use of involved field radiotherapy (RT) and the assessment of clinical response by positron emission tomography (PET). We report our experience on 74 PMLBCL patients treated with a combination of a third-generation chemotherapy regimen (MACOP-B) and rituximab: an observational retrospective single-centre study was conducted on patients diagnosed and treated between February 2002 and July 2011. All patients were evaluated by computed tomography scan and PET scan; after the final PET evaluation, PET-negative patients were observed, whereas PET-positive patients underwent mediastinal RT. Sixty-one (82.4\%) patients achieved a complete response after the MACOP-B plus rituximab regimen; 68.9\% presented a positive final PET and were treated with local RT, whereas 31.1\% had a negative PET. Five patients relapsed within 12 months. At 10 years, overall survival was 82\%, progression-free survival was 87.6\% and disease-free survival (DFS) was 90.5\% (median follow-up 4 years). No statistically significant differences were observed in DFS between the patients treated also with RT (PET positive) and patients only observed (PET negative): 90.7\% vs 90\% (p = 0.85), respectively. In our experience, adding rituximab does not change the final results in terms of complete response and DFS utilizing third-generation regimen. Furthermore, the introduction of the PET-guided RT approach leads to a patient-tailored treatment, which preserves the outcome and, at the same time, allows reducing the use of RT. Copyright © 2014 John Wiley & Sons, Ltd.

Published
2015

14. 90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years

Author

Casadei, Beatrice, primary, Pellegrini, Cinzia, additional, Pulsoni, Alessandro, additional, Annechini, Giorgia, additional, De Renzo, Amalia, additional, Stefoni, Vittorio, additional, Broccoli, Alessandro, additional, Gandolfi, Letizia, additional, Quirini, Federica, additional, Tonialini, Lorenzo, additional, Morigi, Alice, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2016
Full Text
View/download PDF

15. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study

Author

ZINZANI, PIER LUIGI, PELLEGRINI, CINZIA, Merla E., Ballerini F., Fabbri A., Guarini A., Pavone V., Quintini G., Puccini B., Vigliotti M. L., STEFONI, VITTORIO, DERENZINI, ENRICO, BROCCOLI, ALESSANDRO, GANDOLFI, LETIZIA, QUIRINI, FEDERICA, CASADEI, BEATRICE, ARGNANI, LISA, BACCARANI, MICHELE, Zinzani P.L., Pellegrini C., Merla E., Ballerini F., Fabbri A., Guarini A., Pavone V., Quintini G., Puccini B., Vigliotti M.L., Stefoni V., Derenzini E., Broccoli A., Gandolfi L., Quirini F., Casadei B., Argnani L., and Baccarani M.

Subjects
Bortezomib, immune system diseases, hemic and lymphatic diseases, lymphoma
Abstract

Current treatments for non-Hodgkin lymphomas are not optimally effective. Among new agents, bortezomib seems to play a pivotal role in the regulation of several cell pathways involved in the development of lymphomas. After results were obtained with clinical trials, we aimed to observe treatment with bortezomib in everyday clinical practice. We performed a multicenter retrospective analysis to assess the efficacy of bortezomib in heavily pretreated (median number of previous therapies 4, range 2-6) lymphoma patients in an off-label setting. Bortezomib therapy was scheduled for 4-6 cycles (1.3 mg/m2 biweekly). Data from 50 patients were collected: 22% had a complete remission, 26% obtained a partial response and the remaining 52% was non-responder. According to histotype, we observed an overall response rate (ORR) of 51.6% in mantle cell lymphomas, an ORR of 60% among follicular lymphoma patients, and an ORR of 50% in the indolent nonfollicular lymphomas. None of diffuse large B-cell lymphoma patients obtained a response. Extra-hematological toxicity was really mild, and peripheral neuropathy occurred in only 5 patients; hematological toxicity was grades 3-4 thrombocytopenia in nine patients and grades 3-4 neutropenia in only three patients. In conclusion, treatment with bortezomib as single agent resulted safe and effective in a subset of heavily pretreated lymphoma patients with usually poor outcome. New future hypotheses of investigation are indicated. Copyright © 2012 John Wiley & Sons, Ltd.

Published
2013

16. Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis.

Author

Broccoli, Alessandro, Argnani, Lisa, Stefoni, Vittorio, Gandolfi, Letizia, and Zinzani, Pier Luigi

Abstract

Epoetin biosimilars are an alternative to originator erythropoietic agents in the treatment of chemotherapy-induced anaemia; however, their effects in patients with lymphoproliferative disorders remain unclear. This analysis examined the response of patients with lymphoproliferative disorders experiencing chemotherapy-induced anaemia to 4- or 8-week treatment with the biosimilar epoetin alpha. Treatment was initiated at first occurrence of haemoglobin (Hb) < 10 g/dL during chemotherapy and was stopped when Hb was >11 g/dL, when chemotherapy was completed, or in case of transfusion dependency. Response to epoetin alpha was defined as an increase in Hb of >1 g/dL or as an Hb > 11 g/dL. Stability was defined as change in Hb of ±1 g/dL, and no response was indicated by a decrease in Hb of >1 g/dL or acquired transfusion dependence. Overall, 65 patients were enrolled (median age 69 years; 47.7% ≥ 70 years old). Mean Hb levels at the initiation of epoetin alpha was 9.3 ± 0.5 g/dL. Mean Hb levels reached 10.7 ± 1.4 and 10.6 ± 1.5 g/dL at weeks 4 and 8, respectively, in patients on first-line chemotherapy and 11.4 ± 1.6 and 9.7 ± 1.3 g/dL in those on a second- or higher-line regimen. Overall, 70.8% of patients responded, 26.1% had stable Hb, and 3.1% did not respond. Delays or interruption of any chemotherapy cycle due to anaemia occurred in 18 patients. The biosimilar epoetin alpha was well tolerated and allowed patients with non-Hodgkin lymphoma or chronic lymphoproliferative disorders to continue their course of chemotherapy by effectively increasing and maintaining adequate concentrations of Hb. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

17. Brentuximab vedotin followed by ABVD +/− radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study

Author

Federico, Massimo, primary, Luminari, Stefano, additional, Pellegrini, Cinzia, additional, Merli, Francesco, additional, Pesce, Emanuela Anna, additional, Chauvie, Stephane, additional, Gandolfi, Letizia, additional, Capodanno, Isabella, additional, Salati, Massimiliano, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2015
Full Text
View/download PDF

18. 18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse

Author

Broccoli, Alessandro, primary, Zanoni, Lucia, additional, Nanni, Cristina, additional, Montini, Giancarlo, additional, Stefoni, Vittorio, additional, Pellegrini, Cinzia, additional, Gandolfi, Letizia, additional, Fonti, Cristina, additional, Lodi, Filippo, additional, Cavo, Michele, additional, Fanti, Stefano, additional, and Zinzani, Pier Luigi, additional

Published
2015
Full Text
View/download PDF

19. Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

Author

Pellegrini, Cinzia, primary, Broccoli, Alessandro, additional, Casadei, Beatrice, additional, Chiappella, Annalisa, additional, Corradini, Paolo, additional, Derenzini, Enrico, additional, Dodero, Anna, additional, Farina, Lucia, additional, Gandolfi, Letizia, additional, Ladetto, Marco, additional, Monaco, Federico, additional, Orsucci, Lorella, additional, Quirini, Federica, additional, Salvi, Flavia, additional, Spina, Francesco, additional, Stefoni, Vittorio, additional, Tonialini, Lorenzo, additional, Vitolo, Umberto, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2015
Full Text
View/download PDF

20. Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma

Author

Zinzani, Pier Luigi, primary, Gandolfi, Letizia, additional, Casadei, Beatrice, additional, Pellegrini, Cinzia, additional, Broccoli, Alessandro, additional, Derenzini, Enrico, additional, Quirini, Federica, additional, Tonialini, Lorenzo, additional, Cavo, Michele, additional, Argnani, Lisa, additional, and Stefoni, Vittorio, additional

Published
2015
Full Text
View/download PDF

21. Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study

Author

Stefoni, Vittorio, primary, Pellegrini, Cinzia, additional, Gandolfi, Letizia, additional, Baldini, Luca, additional, Tani, Monica, additional, Cencini, Emanuele, additional, Figuera, Amalia, additional, Ansuinelli, Michela, additional, Bernocco, Elisa, additional, Cantonetti, Maria, additional, Cox, M. Christina, additional, Ballerini, Filippo, additional, Rusconi, Chiara, additional, Visco, Carlo, additional, Arcaini, Luca, additional, Fama, Angela, additional, Marasca, Roberto, additional, Zaja, Francesco, additional, Castellino, Alessia, additional, Califano, Catello, additional, Cavaliere, Marina, additional, Gini, Guido, additional, Liberati, Anna Marina, additional, Musuraca, Gerardo, additional, Lucania, Anna, additional, Ricciuti, Giuseppina, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2015
Full Text
View/download PDF

25. Efficacy and Safety of Biosimilar Epoetin Alpha in Patients with Chronic Lymphoproliferative Syndromes and Chemotherapy-Induced Anemia: An Observational, Retrospective, Monocentric Analysis

Author

Broccoli, Alessandro, primary, Casadei, Beatrice, additional, Derenzini, Enrico, additional, Gandolfi, Letizia, additional, Pellegrini, Cinzia, additional, Quirini, Federica, additional, Stefoni, Vittorio, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2014
Full Text
View/download PDF

27. The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients

Author

Zinzani, Pier Luigi, primary, Broccoli, Alessandro, additional, Casadei, Beatrice, additional, Stefoni, Vittorio, additional, Pellegrini, Cinzia, additional, Gandolfi, Letizia, additional, Maglie, Roberto, additional, Argnani, Lisa, additional, Pileri, Stefano, additional, and Fanti, Stefano, additional

Published
2014
Full Text
View/download PDF

30. Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma

Author

Derenzini, Enrico, primary, Stefoni, Vittorio, additional, Casadei, Beatrice, additional, Pellegrini, Cinzia, additional, Broccoli, Alessandro, additional, Fanti, Stefano, additional, Gandolfi, Letizia, additional, Stefani, Giulia, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2013
Full Text
View/download PDF

33. Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients

Author

Broccoli, Alessandro, primary, Stanzani, Marta, additional, Bandini, Giuseppe, additional, Bonifazi, Francesca, additional, Stefoni, Vittorio, additional, Pellegrini, Cinzia, additional, Derenzini, Enrico, additional, Gandolfi, Letizia, additional, Quirini, Federica, additional, Argnani, Lisa, additional, Tschon, Marta, additional, Casadei, Beatrice, additional, Baccarani, Michele, additional, and Zinzani, Pier Luigi, additional

Published
2012
Full Text
View/download PDF

34. Extranodal marginal zone B‐cell lymphoma of the lung: experience with fludarabine and mitoxantrone‐containing regimens

Author

Zinzani, Pier Luigi, primary, Pellegrini, Cinzia, additional, Gandolfi, Letizia, additional, Casadei, Beatrice, additional, Derenzini, Enrico, additional, Broccoli, Alessandro, additional, Quirini, Federica, additional, Argnani, Lisa, additional, Pileri, Stefano, additional, Celli, Monica, additional, Fanti, Stefano, additional, Poletti, Venerino, additional, Stefoni, Vittorio, additional, and Baccarani, Michele, additional

Published
2012
Full Text
View/download PDF

35. Collection of Hematopoietic Stem Cells After Previous Exposure to Ittrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma.

Author

Derenzini, Enrico, primary, Pellegrini, Cinzia, additional, Maglie, Roberto, additional, Stefoni, Vittorio, additional, Broccoli, Alessandro, additional, Gandolfi, Letizia, additional, Casadei, Beatrice, additional, Quirini, Federica, additional, Argnani, Lisa, additional, Fanti, Stefano, additional, Motta, Maria Rosa, additional, Baccarani, Michele, additional, and Zinzani, Pier Luigi, additional

Published
2012
Full Text
View/download PDF

36. Fludarabine, Mitoxantrone and Rituximab (FMR) Regimen in Previously Untreated Patients with Indolent Non-Hodgkin Lymphoma: Efficacy, Safety and PET Data On 285 Patients.

Author

Zinzani, Pier Luigi, primary, Pellegrini, Cinzia, additional, Derenzini, Enrico, additional, Broccoli, Alessandro, additional, Gandolfi, Letizia, additional, Stefoni, Vittorio, additional, Casadei, Beatrice, additional, Quirini, Federica, additional, and Argnani, Lisa, additional

Published
2012
Full Text
View/download PDF

37. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study

Author

Zinzani, Pier Luigi, primary, Pellegrini, Cinzia, additional, Merla, Emanuela, additional, Ballerini, Filippo, additional, Fabbri, Alberto, additional, Guarini, Attilio, additional, Pavone, Vincenzo, additional, Quintini, Gerlando, additional, Puccini, Benedetta, additional, Vigliotti, Maria Luigia, additional, Stefoni, Vittorio, additional, Derenzini, Enrico, additional, Broccoli, Alessandro, additional, Gandolfi, Letizia, additional, Quirini, Federica, additional, Casadei, Beatrice, additional, Argnani, Lisa, additional, and Baccarani, Michele, additional

Published
2012
Full Text
View/download PDF

38. Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.

Author

Zinzani, Pier Luigi, primary, Derenzini, Enrico, additional, Pellegrini, Cinzia, additional, Rigacci, Luigi, additional, Fabbri, Alberto, additional, Quirini, Federica, additional, Stefoni, Vittorio, additional, Gandolfi, Letizia, additional, Argnani, Lisa, additional, Casadei, Beatrice, additional, Broccoli, Alessandro, additional, Pulsoni, Alessandro, additional, Gobbi, Marco, additional, Perrotti, Alessio, additional, Zaccaria, Alfonso, additional, Voso, Maria Teresa, additional, Cabras, Maria Giuseppina, additional, Renzo, Amalia De, additional, and Baccarani, Michele, additional

Published
2011
Full Text
View/download PDF

40. Early Interim 18f-FDG PET In Hodgkin's Lymphoma: Evaluation on 304 Patients

Author

Zinzani, Pier Luigi, primary, Rigacci, Luigi, additional, Stefoni, Vittorio, additional, Broccoli, Alessandro, additional, Puccini, Benedetta, additional, Gandolfi, Letizia, additional, Fanti, Stefano, additional, Castagnoli, Antonio, additional, Pellegrini, Cinzia, additional, Montini, Gian Carlo, additional, Quirini, Federica, additional, Antognoli, Giulia, additional, Vaggelli, Luca, additional, Derenzini, Enrico, additional, Argnani, Lisa, additional, Ambrosini, Valentina, additional, Agostinelli, Claudio, additional, Pileri, Stefano A., additional, Bosi, Alberto, additional, and Baccarani, Michele, additional

Published
2010
Full Text
View/download PDF

42. Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

Author

Zinzani, Pier Luigi, primary, Rossi, Giuseppe, additional, Franceschetti, Silvia, additional, Botto, Barbara, additional, Di Rocco, Alice, additional, Cabras, Maria Giuseppina, additional, Petti, Maria Concetta, additional, Stefoni, Vittorio, additional, Broccoli, Alessandro, additional, Fanti, Stefano, additional, Pellegrini, Cinzia, additional, Montini, Gian Carlo, additional, Gandolfi, Letizia, additional, Derenzini, Enrico, additional, Argnani, Lisa, additional, Fina, Mariapaola, additional, Tucci, Alessandra, additional, Bottelli, Chiara, additional, Pileri, Stefano, additional, and Baccarani, Michele, additional

Published
2010
Full Text
View/download PDF

43. Hairy cell leukemia

Author

Zinzani, Pier Luigi, primary, Pellegrini, Cinzia, additional, Stefoni, Vittorio, additional, Derenzini, Enrico, additional, Gandolfi, Letizia, additional, Broccoli, Alessandro, additional, Argnani, Lisa, additional, Quirini, Federica, additional, Pileri, Stefano, additional, and Baccarani, Michele, additional

Published
2010
Full Text
View/download PDF

44. A Phase II Trial of Rituximab-CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (90Y-IT) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

Author

Zinzani, Pier Luigi, primary, Fina, Mariapaola, additional, Tani, Monica, additional, Stefoni, Vittorio, additional, Gandolfi, Letizia, additional, Broccoli, Alessandro, additional, Pellegrini, Cinzia, additional, Derenzini, Enrico, additional, Rossi, Giuseppe, additional, Angelucci, Emanuele, additional, Gaidano, Gianluca, additional, Petti, Maria Concetta, additional, Martelli, Maurizio, additional, Vitolo, Umberto, additional, Fanti, Stefano, additional, and Baccarani, Michele, additional

Published
2009
Full Text
View/download PDF

45. Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.

Author

Stefoni, Vittorio, primary, Broccoli, Alessandro, additional, Alinari, Lapo, additional, Ambrosini, Valentina, additional, Derenzini, Enrico, additional, Fanti, Stefano, additional, Fina, Mariapaola, additional, Gandolfi, Letizia, additional, Marchi, Enrica, additional, Pellegrini, Cinzia, additional, Quirini, Federica, additional, Zinzani, Pier Luigi, additional, and Baccarani, Michele, additional

Published
2009
Full Text
View/download PDF

46. A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (90Y-IT) for Untreated Follicular Lymphoma (FL) Patients.

Author

Zinzani, Pier Luigi, primary, Tani, Monica, additional, Broccoli, Alessandro, additional, Derenzini, Enrico, additional, Pulsoni, Alessandro, additional, De Renzo, Amalia, additional, Fanti, Stefano, additional, Fina, Mariapaola, additional, Gandolfi, Letizia, additional, Pellegrini, Cinzia, additional, Stefoni, Vittorio, additional, and Baccarani, Michele, additional

Published
2009
Full Text
View/download PDF

47. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0–1) diffuse large B-cell lymphoma

Author

Derenzini, Enrico, primary, Stefoni, Vittorio, additional, Pellegrini, Cinzia, additional, Fina, Maria Paola, additional, Broccoli, Alessandro, additional, Venturini, Filippo, additional, Gandolfi, Letizia, additional, Pileri, Stefano A., additional, Martelli, Maurizio, additional, Petti, Maria Concetta, additional, Perrotti, Alessio, additional, De Renzo, Amalia, additional, Zaja, Francesco, additional, Baccarani, Michele, additional, and Zinzani, Pier Luigi, additional

Published
2009
Full Text
View/download PDF

48. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.

Author

Zinzani, Pier Luigi, Pellegrini, Cinzia, Broccoli, Alessandro, Gandolfi, Letizia, Stefoni, Vittorio, Casadei, Beatrice, Maglie, Roberto, Argnani, Lisa, and Pileri, Stefano

Subjects
ANTINEOPLASTIC agents, ANTIMETABOLITES, ANTIVIRAL agents, B cell lymphoma, CANCER relapse, DRUG therapy, CHRONIC lymphocytic leukemia, IMMUNOTHERAPY, LYMPHOMAS, PROGNOSIS, TREATMENT effectiveness, RETROSPECTIVE studies, MITOXANTRONE
Abstract

Indolent non-follicular lymphomas (inFLs) are generally regarded as incurable, apart from extranodal mucosa-associated lymphatic tissue lymphomas, which can be partially cured by surgery, local radiotherapy, or antibiotic treatment. The aim of the present study was to test the degree of effectiveness and the safety of the regimen containing fludarabine, mitoxantrone, and rituximab (FMR) in inFL patients considering all the different entities belonging to this group. An observational retrospective study was conducted on 143 inFL patients providing that their first chemoimmunotherapy performed was FMR regimen and diagnosis from September 2000 to March 2011. There were 32 small lymphocytic lymphomas and 111 marginal zone lymphomas. At the end of treatment, overall response rate was 96.5% with 88% of complete responses (CR) and 8.5% of partial responses. With a median follow-up of 48 months, 10 out of 125 (8%) CR patients had disease relapse, yielding an estimated 9-year disease-free survival (DFS) of 74.9% and an estimated 10-year overall survival of 92.8%. The estimated 9-year progression free survival was 70.5%. The 10 relapsed patients showed lymphoma recurrence within 52 months: after this time, the DFS curve presented a plateau configuration. Only two (1.4%) patients developed a secondary hematological neoplasia. This study showed promising findings for the use of a fludarabine-based regimen in combination with rituximab in the front-line treatment of symptomatic inFL with a noteworthy high percentage of CR associated to an interesting long-term DFS and favorable acute and long-term safety profile. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

49. Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.

Author

Zinzani, Pier Luigi, Pellegrini, Cinzia, Gandolfi, Letizia, Casadei, Beatrice, Derenzini, Enrico, Broccoli, Alessandro, Quirini, Federica, Argnani, Lisa, Pileri, Stefano, Celli, Monica, Fanti, Stefano, Poletti, Venerino, Stefoni, Vittorio, and Baccarani, Michele

Abstract

Bronchial-associated lymphoid tissue (BALT) lymphoma is an extranodal primary pulmonary lymphoma. The optimal therapy for this rare disease is still debated, and few heterogeneous data are available in literature. The aim of our study was to critically review data of patients with BALT lymphoma treated in first-line therapy with fludarabine and mitoxantrone-containing regimens (with or without rituximab) to investigate the effectiveness and the safety of this approach and patients' survival. An observational retrospective study was performed on homogenous clinical data from 17 patients with biopsy-proven diagnosis of BALT. All the patients were treated with fludarabine and mitoxantrone-containing regimen therapy. Radiological findings were also reviewed to assess the role of 18fluoro-deoxyglucose positron emission tomography in the initial assessment and in the monitoring of this extranodal lymphoma. A high percentage of response was observed: 82.3% of patients achieved a complete response, 11.8% a partial response. Furthermore, a very remarkable progression-free survival (71%) and overall survival (100%) were estimated at 14 years. No relevant toxicities were registered. Our results support the use of fludarabine and mitoxantrone-containing regimens as first-line therapy in the treatment of BALT lymphoma even if further data are necessary to consolidate our findings. Positron emission tomography scanning may provide additional valuable information in the assessment of BALT lymphoma. Copyright © 2012 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

50. Midtreatment.

Author

Zinzani, Pier Luigi, Gandolfi, Letizia, Broccoli, Alessandro, Argnani, Lisa, Fanti, Stefano, Pellegrini, Cinzia, Stefoni, Vittorio, Derenzini, Enrico, Quirini, Federica, and Baccarani, Michele

Subjects
*HODGKIN'S disease, *POSITRON emission tomography, *IMMUNOTHERAPY, *B cell lymphoma, *LYMPHOMAS
Abstract

BACKGROUND: The use of 18F-fluorodeoxyglucose positron-emission tomography (PET) scan has increased considerably in the clinical management of non-Hodgkin lymphoma patients, and its role as a prognostic factor during chemotherapy has been established recently. METHODS: Between May 2003 and May 2009, 91 newly diagnosed patients with primary mediastinal large B-cell lymphoma (PMLBCL) and diffuse large B-cell lymphoma (DLBCL) were treated with 12 weekly cycles of rituximab-MACOP-B (n = 12 patients with PMLBCL), 6 cycles of rituximab-CHOP21 (n = 65 patients with DLBCL, aged < 60 years and 1 patient with PMLBCL), or 8 weekly cycles of rituximab-VNCOPB (n = 13 DLBCL patients, aged ≥ 60 years). All patients underwent a staging PET examination at baseline and a midtreatment (interim) PET examination after 6 weeks of rituximab-MACOP-B treatment, 3 cycles of rituximab-CHOP21 treatment, or 4 weeks of rituximab-VNCOP-B treatment and again at the end of the chemo-immunotherapy regimen. RESULTS: At midtreatment evaluation, 35 patients showed a persistently positive PET scan; only 6 (17%) of these patients achieved a continuous complete response (CCR). However, 56 patients presented with a negative interim PET, and 50 (89%) of these patients achieved and maintained a CCR. Comparison between the 2 PET groups indicated a statistically significant association between PET findings and event-free survival (P = .0001) and overall survival (P = .0001). CONCLUSIONS: The results of this study indicated that midtreatment PET may represent a significant step forward in helping physicians make crucial decisions on further treatment. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results